UNASSIGNED: Liver thermal ablation is an alternative treatment for @entity157 ( @entity157 ) and secondary @entity409 . Microwave ablation (MWA) produces large ablation zones (AZ) in short time; however, AZ prediction is based on preclinical ex vivo models, rising concerns about reproducibility and safety in @entity1 . We aimed to investigate the effects produced by a new-generation MWA system on @entity1 liver in vivo with different approaches (percutaneous or intraoperative) and @entity409 ( @entity82 or previous chemotherapy treatment), in comparison with manufacturer-provided predictions based on ex vivo animal models. @entity5 ( @entity5 ) and early clinical outcomes were also assessed. From October 2014, 60 consecutive @entity1 (cirrhotic  =  31; non-cirrhotic  =  10; chemotherapy-treated  =  19) with 81 liver nodules ( @entity157  =  31; mets  =  50) underwent MWA procedures (percutaneous  =  30; laparotomic  =  18; laparoscopic  =  12), with a 2450  MHz/100  W generator with Thermosphere    Technology (Emprint   , Medtronic). A contrast-enhanced CT or MR was performed after one month to assess @entity5 and measure AZ. A linear correlation between AZ volumes and ablation times was observed in vivo, without differences from manufacturer-provided ex vivo predictions in all operative approaches and @entity409 . Other independent variables (sex, age, nodule location) showed no relationship when added to the model. Median (IQR) longitudinal and transverse roundness-indexes of the AZs were, respectively, 0.77(0.13) and 0.93(0.11). @entity5 at 1 month was 93% for percutaneous and 100% for intraoperative procedures (p  =  0.175). Thirty-day morbidity and mortality were 3% and 0%. MWA with Thermosphere    Technology produces predictable AZs on @entity1 liver in vivo, according to manufacturer-provided ex vivo predictions. In our experience, this new-generation MWA system is effective and safe to treat @entity409 in different operative and clinical settings.

Microwave ablation of XXXX : comparison of effects and early outcomes of percutaneous and intraoperative approaches with different @entity409 : New advances in interventional oncology: state of the art.

@entity1 :: ('9606', 'Species') :: ['humans', 'human', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Complete tumor ablation', 'CA'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver malignancies', 'liver conditions'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']
@entity409 :: (MESH:D008107,Disease) :: ['liver malignancies']
